What is MOKSHA8 PHARMACEUTICALS?
Founded in 2007 and headquartered in Berwyn, Pennsylvania, Moksha8 Pharmaceuticals operates as a specialized commercialization platform focused on delivering high-quality therapeutic solutions to Latin American patients. The company distinguishes itself through a robust operational framework that prioritizes FCPA compliance and best-in-class distribution standards. Since launching commercial operations in 2008, Moksha8 has cultivated a diverse portfolio, with a primary emphasis on Central Nervous System (CNS) products. Its market position is bolstered by strategic alliances with industry leaders such as GSK, Sandoz, Aurobindo, and Accord, enabling the firm to effectively scale its footprint across high-growth territories while maintaining stringent quality control protocols.
How much funding has MOKSHA8 PHARMACEUTICALS raised?
MOKSHA8 PHARMACEUTICALS has raised a total of $219.1M across 4 funding rounds:
Series A
$39M
Series B
$25.1M
Series C
$30M
Unspecified
$125M
Series A (2008): $39M with participation from TPG Biotech
Series B (2009): $25.1M led by Montreux Equity Partners
Series C (2010): $30M supported by Watson
Unspecified (2012): $125M featuring Forest Laboratories
Key Investors in MOKSHA8 PHARMACEUTICALS
Forest Laboratories
A former pharmaceutical powerhouse known for licensing and commercializing European medical innovations for the North American market.
TPG Biotech
A specialized investment arm of TPG Capital focusing on life sciences and healthcare innovation across various stages of development.
Montreux Equity Partners
A private equity firm dedicated to investing in growth-stage healthcare companies that demonstrate significant potential for market disruption.
What's next for MOKSHA8 PHARMACEUTICALS?
With a history of successful capital raises dating back to its Series A in 2008, Moksha8 is well-positioned to leverage its recent strategic investment to deepen its market penetration. The company's forward-looking strategy likely involves expanding its therapeutic pipeline and strengthening its existing partnerships to capture a larger share of the Latin American pharmaceutical market. As the firm continues to mature, the focus will remain on optimizing its commercial infrastructure and exploring new licensing opportunities that align with its core competency in CNS therapeutics. By maintaining its commitment to operational transparency and strategic collaboration, Moksha8 is poised to remain a vital conduit for pharmaceutical access in the region.
See full MOKSHA8 PHARMACEUTICALS company page
